• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Mylan may have overcharged US by $1.3B for EpiPen

May 31, 2017 By Sarah Faulkner

MylanMylan (NSDQ:MYL) shares dipped slightly in mid-afternoon trading today after Sen. Chuck Grassley’s (R-Iowa) office released a Health and Human Services estimate claiming that taxpayers overpaid by as much as $1.27 billion for Mylan’s EpiPen device from 2006 to 2016.

The charges stem from Mylan’s decision to classify the emergency allergy auto-injector as a generic, instead of a branded product under the Medicaid Drug Rebate Program. Misclassifying the device allowed the company to pay the government a 13% rebate instead of a 23% rebate. The Centers for Medicare and Medicaid Services repeatedly warned Mylan that the device was wrongly classified, but the company didn’t take action.

The Medicaid Drug Rebate Program includes CMS, state agencies and participating drug manufacturers and it exists to offset the federal and state costs of prescription drugs dispensed to Medicaid patients. Nearly 600 drug manufacturers participate in the program, according to the federal government.

The program requires drugmakers to ink a national rebate agreement with the Dept. of Health and Human Services in exchange for state Medicaid coverage of the company’s drugs. Manufacturers are responsible for paying a rebate on drugs that are covered by the state and those rebates are determined based upon the type of drug – including whether it’s a branded drug or a generic drug.

Last fall, Mylan agreed to dish out $465 million to settle allegations that it underpaid Medicaid for the auto-injector. The company and the Dept. of Justice declined to attend a Senate hearing in November regarding the settlement, saying that it was a “pending matter”.

Canonsburg, Pa.-based Mylan has been under fire since August, when reports surfaced that it raised the price of its EpiPen product by more than 500% over the past decade.

Also today, reports revealed that major institutional investors are urging shareholders to vote down 6 members of Mylan’s board, including the chairman.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Mylan

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS